While we are not primarily focused on the corporate landscape in CLL, it makes sense to stay abreast of the business news that might influence what drugs get to market and how fast, what combinations are explored in clinical trials, what’s it will eventually cost, how good is insurance coverage, and what kind of support and education will be offered.
This is big news. There are already trials in the works for the combination Abbvie’s ABT-199 (venetoclax) and Pharmacyclics’ ibrutinib (Imbruvica).
Here is a link to the story from the New York Times.
